Home › Kanser sa Ovary › New York › New York City
Pag-aaral pangklinika para sa Kanser sa Ovary sa New York City, NY
69 pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng New York City (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Nagre-recruitPhase 1/2
- Research Site, New York
- Research Site, New York
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Nagre-recruitPhase 2/3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Nagre-recruit
- Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Nagre-recruitPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Mount Sinai, New York
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- at 2 pa
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- Memorial Sloan Kettering Hospital, New York
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Nagre-recruit
- Mount Sinai Health System, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Nagre-recruitPhase 1
- Research Site, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Avenzo Therapeutics Recruiting Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Nagre-recruitObservasyonal na pag-aaral
- NYU Langone Medical Center, New York
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Nagre-recruitPhase 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Nagre-recruitPhase 3
- Laura and Isaac Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Nagre-recruitPhase 2
- Columbia University Medical Center /ID# 277990, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Nagre-recruitPhase 3
- Memorial Sloan Kettering Cancer Center ( Site 0072), New York
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Nagre-recruitPhase 2
- Laura and Isaac Perlmutter Cancer Center, New York
A Study of Isoquercetin in People With Ovarian Cancer
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Nagre-recruitPhase 1/2
- Mount Sinai, New York
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Nagre-recruitPhase 3
- Columbia University Medical Center, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Nagre-recruitPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Nagre-recruitPhase 3
- Laura and Isaac Perlmutter Cancer Center ( Site 0076), New York
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Nagre-recruitPhase 1/2
- Start Nyli, New York
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nagre-recruitPhase 1
- New York Cancer & Blood Specialists, New York
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Icahn School of Medicine at Mount Sinai, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Xencor Investigative Site, New York
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Nagre-recruitPhase 1/2
- Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Nagre-recruit
- Mount Sinai Chelsea, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai West, New York
- at 4 pa
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Nagre-recruitPhase 3
- Mount Sinai Chelsea, New York
- Bellevue Hospital Center, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- at 3 pa
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Nagre-recruitPhase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Clinical Pre-screening Protocol for Ovarian Cancer
Nagre-recruitObservasyonal na pag-aaral
- The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Nagre-recruitPhase 2/3
- NYU Langone Health, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Nagre-recruitPhase 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Investigative Site #103, New York
- Investigative Site #106, New York
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Nagre-recruitPhase 3
- Mount Sinai, New York
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Nagre-recruitPhase 1/2
- Mt Sinai Hospital, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center, New York
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Nagre-recruitPhase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Nagre-recruit
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Nagre-recruitPhase 1/2
- NYU Langone Medical Center, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 2
- USA04-0, New York
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Nagre-recruitPhase 3
- Memorial Sloan-Kettering Cancer Center, New York
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Nagre-recruitPhase 1
- Site 0173, New York
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Nagre-recruit
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Nagre-recruitPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Nagre-recruitPhase 1
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Nagre-recruitPhase 1
- NYU Cancer Institute Clinical Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, New York
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #5, New York
NYSCF Scientific Discovery Biobank
Nagre-recruitObservasyonal na pag-aaral
- New York Stem Cell Foundation Research Institute, New York
Comprehensive Outcomes for After Cancer Health
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Memorial Sloan Kettering Cancer Center, New York
Pag-aaral para sa Kanser sa Ovary sa ibang lungsod
- Houston, TX89 pag-aaral
- Boston, MA61 pag-aaral
- Los Angeles, CA50 pag-aaral
- Nashville, TN49 pag-aaral
- Arlington, VA46 pag-aaral
- Philadelphia, PA44 pag-aaral
- Columbus, OH39 pag-aaral
- St. Louis, MO38 pag-aaral
- Chicago, IL36 pag-aaral
- San Antonio, TX31 pag-aaral
- Cleveland, OH30 pag-aaral
- Pittsburgh, PA30 pag-aaral
Iba pang pag-aaral sa New York City
- Kanser sa Suso136 pag-aaral
- Non-Small Cell Lung Cancer121 pag-aaral
- Kanser (lahat ng uri)109 pag-aaral
- Kanser sa Prostate103 pag-aaral
- Metastatic Cancer93 pag-aaral
- Colorectal Cancer78 pag-aaral
- Kanser sa Baga60 pag-aaral
- Multiple Myeloma60 pag-aaral
- Kanser sa Pancreas60 pag-aaral
- Kanser ng Endometrium52 pag-aaral
- Acute Myeloid Leukemia51 pag-aaral
- Pagkabigo ng Puso51 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.